Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Affiliations

• ¹ Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ² Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. [email protected].
• ³ , 10 Center Dr; Building 10, Room 1-5950, Bethesda, MD, 20892, USA. [email protected].
• ⁴ Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁵ Division of Urologic Oncology, Department of Urology, NYU Langone Health, NYU School of Medicine, New York, NY, USA.
• ⁶ Department of Urology, Michigan Medicine, Ann Arbor, MI, USA.
• ⁷ Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
• ⁸ Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Department of Urology, Istanbul Medipol University, Istanbul, Turkey.